MA5-32651

antibody from Invitrogen Antibodies

Targeting: CTSB

Western blot

Antibody data

Submit

Validation data

Product number: MA5-32651 - Provider product page
Provider: Invitrogen Antibodies
Product name: Cathepsin B Recombinant Rabbit Monoclonal Antibody (JA11-02)
Antibody type: Monoclonal
Antigen: Recombinant full-length protein
Description: Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.
Reactivity: Human
Host: Rabbit
Isotype: IgG
Antibody clone number: JA11-02
Vial size: 100 µL
Concentration: 1 mg/mL
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

CTSB protein structure - MA5-32651 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of Cathepsin B of paraffin-embedded Human liver cancer tissue using a Cathepsin-B Monoclonal antibody (Product #MA5-32651). Counter stained with hematoxylin.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of Cathepsin B of paraffin-embedded Human liver tissue using a Cathepsin-B Monoclonal antibody (Product #MA5-32651). Counter stained with hematoxylin.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of Cathepsin B of paraffin-embedded Human pancreas tissue using a Cathepsin-B Monoclonal antibody (Product #MA5-32651). Counter stained with hematoxylin.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of Cathepsin B of paraffin-embedded Mouse liver tissue using a Cathepsin-B Monoclonal antibody (Product #MA5-32651). Counter stained with hematoxylin.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of Cathepsin B of paraffin-embedded Mouse pancreas tissue using a Cathepsin-B Monoclonal antibody (Product #MA5-32651). Counter stained with hematoxylin.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of Cathepsin B of paraffin-embedded Mouse brain tissue using a Cathepsin-B Monoclonal antibody (Product #MA5-32651). Counter stained with hematoxylin.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 cGMP but not PKG-I is involved in non-canonical and alternative inflammasome activation. THP-1 cells were pre-treated for 10 min with ANP (10 -8 M) or BNP (10 -8 M) or cGMP (100 µM 8-Br-cGMP) in the absence or presence of LPS (10 µg/mL for 20 min) + ATP (5 mM for 40 min). When KT-5823 (1 muM) or 3-isobutyl-1-methylxanthine (IBMX) (10 muM) were used, they were added 1 h before ANP, BNP, or 8-Br-cGMP treatment. Cell lysates were immunoblotted for active Cathepsin B ( A ), Gasdermin D ( B , E ), RIPK1 ( C ), or Caspase-8 ( D , F ). Protein loading was assessed by re-probing the blots with an anti-beta-actin antibody. One representative image is shown. Representative western blots images are shown. Histograms of densitometric quantification. Bars represent the ratio between respective protein and beta-actin band intensity. Untreated cells were used as control and assumed as 1. All histograms indicate mean +- SD of at least n = three independent experiments, each one tested in triplicate. * p < 0.05, ** p < 0.01, *** p < 0.001 versus untreated cells; deg p < 0.05, degdeg p < 0.01 and degdegdeg p < 0.001 versus LPS + ATP treated cells; # p < 0.05 versus KT-5823 + LPS + ATP treated cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 U87 cells have no detectable endogenous ACE2 expression but high levels of Cathepsin B. A) Different cell lines were analyzed for ACE2 expression by immunoblotting, with beta-actin as loading control. B) Same as in (A) but with the stably ACE2 transduced U87 cells, tested at an early (# 1) or late (# 32) passage of the cells. The transduced U87 cells stably express ACE2 at a very high level as compared to endogenous ACE2 in the Vero E6 cells. The same immunoblot is used for panel A and B, but with a longer exposure time for panel A in order to visualize the faint band in the Calu-3 sample. C) Comparative qPCR analysis of TMPRSS2 mRNA levels in different cells. Graph shows individual copy numbers/mul of 3 technical replicates (n = 3) as calculated from a TMPRSS2 standard. The TMPRSS2 level in Vero E6 cells was below detection limit. D) Different cell lines were analyzed for Cathepsin L (CTSL; left) and Cathepsin B (CTSB; right) expression by immunoblotting, with clathrin as loading control. For CTSL, different species are detected (indicated by the bracket): Pro-CTSL (41 kDa), glycosylated mature CTSL (31 kDa) and non-glycosylated mature CTSL (25 kDa), whereas only the Pro-CTSB form (42 kDa) is visualized. M: molecular marker in kDa, UD: undetectable. Fig. 1